CN109735623A - A kind of colorectal cancer biomarker - Google Patents
A kind of colorectal cancer biomarker Download PDFInfo
- Publication number
- CN109735623A CN109735623A CN201910173715.XA CN201910173715A CN109735623A CN 109735623 A CN109735623 A CN 109735623A CN 201910173715 A CN201910173715 A CN 201910173715A CN 109735623 A CN109735623 A CN 109735623A
- Authority
- CN
- China
- Prior art keywords
- gene
- nucleic acid
- sequence
- colorectal cancer
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 36
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 27
- 239000000107 tumor biomarker Substances 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 238000005516 engineering process Methods 0.000 claims abstract description 19
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 230000003321 amplification Effects 0.000 claims description 19
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 238000012163 sequencing technique Methods 0.000 claims description 15
- 238000003752 polymerase chain reaction Methods 0.000 claims description 14
- 238000009396 hybridization Methods 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 101700073590 ADM5 Proteins 0.000 claims description 6
- 102100034402 ATP-dependent RNA helicase DDX39A Human genes 0.000 claims description 6
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims description 6
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 6
- 102100027557 Calcipressin-1 Human genes 0.000 claims description 6
- 102100034791 Centrosomal protein of 78 kDa Human genes 0.000 claims description 6
- 101710117840 Centrosomal protein of 78 kDa Proteins 0.000 claims description 6
- 102100039221 Cytoplasmic polyadenylation element-binding protein 3 Human genes 0.000 claims description 6
- 108700010013 HMGB1 Proteins 0.000 claims description 6
- 101150021904 HMGB1 gene Proteins 0.000 claims description 6
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 6
- 102100034535 Histone H3.1 Human genes 0.000 claims description 6
- 101000923749 Homo sapiens ATP-dependent RNA helicase DDX39A Proteins 0.000 claims description 6
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 6
- 101000580357 Homo sapiens Calcipressin-1 Proteins 0.000 claims description 6
- 101000745755 Homo sapiens Cytoplasmic polyadenylation element-binding protein 3 Proteins 0.000 claims description 6
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 claims description 6
- 101001053809 Homo sapiens Kinetochore-associated protein DSN1 homolog Proteins 0.000 claims description 6
- 101001139112 Homo sapiens Krueppel-like factor 9 Proteins 0.000 claims description 6
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims description 6
- 101000826081 Homo sapiens SRSF protein kinase 1 Proteins 0.000 claims description 6
- 101000800580 Homo sapiens Transcription factor 19 Proteins 0.000 claims description 6
- 101000836173 Homo sapiens Tumor protein p53-inducible nuclear protein 2 Proteins 0.000 claims description 6
- 101000655533 Homo sapiens dTDP-D-glucose 4,6-dehydratase Proteins 0.000 claims description 6
- 102100024062 Kinetochore-associated protein DSN1 homolog Human genes 0.000 claims description 6
- 102100020684 Krueppel-like factor 9 Human genes 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 102100024923 Protein kinase C beta type Human genes 0.000 claims description 6
- 102100026654 Putative adrenomedullin-5-like protein Human genes 0.000 claims description 6
- 102100023010 SRSF protein kinase 1 Human genes 0.000 claims description 6
- 102100023152 Scinderin Human genes 0.000 claims description 6
- 101710190410 Staphylococcal complement inhibitor Proteins 0.000 claims description 6
- 102100033159 Transcription factor 19 Human genes 0.000 claims description 6
- 102100027218 Tumor protein p53-inducible nuclear protein 2 Human genes 0.000 claims description 6
- 102100032354 dTDP-D-glucose 4,6-dehydratase Human genes 0.000 claims description 6
- 108091027963 non-coding RNA Proteins 0.000 claims description 5
- 102000042567 non-coding RNA Human genes 0.000 claims description 5
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000007834 ligase chain reaction Methods 0.000 claims description 4
- 102100034690 Delta(14)-sterol reductase LBR Human genes 0.000 claims description 3
- 101000945982 Homo sapiens Delta(14)-sterol reductase LBR Proteins 0.000 claims description 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 3
- 101000607984 Homo sapiens Uronyl 2-sulfotransferase Proteins 0.000 claims description 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 3
- 102100039838 Uronyl 2-sulfotransferase Human genes 0.000 claims description 3
- -1 WAS Proteins 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000010240 RT-PCR analysis Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 230000004186 co-expression Effects 0.000 abstract description 6
- 230000002068 genetic effect Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000013399 early diagnosis Methods 0.000 abstract description 2
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 239000000091 biomarker candidate Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108020005198 Long Noncoding RNA Proteins 0.000 description 9
- 238000007901 in situ hybridization Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108091093094 Glycol nucleic acid Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 108091046915 Threose nucleic acid Proteins 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 108091087492 miR-490 stem-loop Proteins 0.000 description 2
- 108091036400 miR-490-1 stem-loop Proteins 0.000 description 2
- 108091057695 miR-490-2 stem-loop Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000007671 third-generation sequencing Methods 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 101000825428 Homo sapiens Protein Shroom4 Proteins 0.000 description 1
- 206010023804 Large intestine perforation Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038019 Rectal adenocarcinoma Diseases 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000029565 malignant colon neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091074709 miR-1183 stem-loop Proteins 0.000 description 1
- 108091039097 miR-193b stem-loop Proteins 0.000 description 1
- 108091091687 miR-592 stem-loop Proteins 0.000 description 1
- 108091024098 miR-938 stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001281 rectum adenocarcinoma Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000006863 thiophosphorylation reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of colorectal cancer biomarkers, are specifically related to colon cancer biomarker LOC105375434 and its co-expression gene.The spininess of colorectal cancer genetic test at present is to therapeutic scheme, early diagnosis research is insufficient, expression of the 1ncRNAs in tumor tissues has tissue and species specificity, it is good Tumor biomarkers, inventor has found the LOC105375434 closely related with colorectal cancer based on high throughput sequencing technologies, new candidate biomarker is provided for the early detection of colorectal cancer, there is potential clinical value.
Description
Technical field
The invention belongs to Cancer Molecular diagnostic fields, and in particular to biomarker relevant to colorectal cancer and its make
Application in standby diagnosis of colon cancer reagent more particularly relates to LOC105375434 and its co-expression gene and examines in preparation colon cancer
Application in disconnected reagent.
Background technique
Colorectal cancer (colorectal, CRC) is one of most common malignant tumour, and colonoscopy is the gold of colorectal cancer screening
Standard, but this method is since costly, patient are painful big, and the complication such as perforation of colon can occur, and can't make at present
Screening implement is generally investigated for colorectal cancer, and is more suitable for the further inspection after preliminary screening." 2015NCCN guide " proposes: institute
Some PATIENTS WITH LARGE BOWELs should all inquire that family history, doubtful heredity PATIENTS WITH LARGE BOWEL should carry out corresponding science of heredity detection, do
Early prevention is found to early, early diagnoses early treatment.By technique of gene detection screening colorectal cancer people at highest risk, so that cancer is suffered from prediction
Risk accomplishes to intervene early and prevent, and saves treatment time and cost；Secondly, can be examined by gene for colorectal cancer patients
Survey technology excavates pathogenesis, to provide targeted treatment schemes and predict that other suffer from cancer risk.
The most common genetic test of colorectal cancer at present has RAS detection: finding the patient of transfer stove, carries out tumor tissues K-
Ras and the detection of the 2nd, 3,4 exon of N-ras, RAS gene mutation prompt tumour to targeting epidermal growth factor receptor antibody without controlling
Treat reaction；In addition there are BRAF detections: RAS gene wild type patient should row BRAF detection, there are mutation person prompt prognosis mala.
But for colorectal cancer genetic test spininess to therapeutic scheme, early diagnosis research is insufficient at present, although it has been reported that part and knot
Rectum cancer associated gene miR-1183, miR-938, miR-490-3p, miR-490-5p, miR-592, miR-193b
(ZL201510204297.8), SHROOM4 (ZL 2016100689102) etc., but these genes are also far from satisfying knot
The clinical molecular diagnosis of the carcinoma of the rectum still has a large amount of marker genes urgently to excavate.
The study found that the occurrence and development of long-chain non-coding RNA (long non-coding RNAs, IncRNAs) and tumour
With important relationship, the 1ncRNAs expression in tumor tissues is often abnormal, and has tissue and species specificity, and 1ncRNAs is
A kind of good Tumor biomarkers, the early screening for tumour.Inventor to the cancerous tissue and cancer of Colon and rectum patient by
Tissue carries out transcript profile sequencing analysis, finds the apparent 1ncRNAs of differential expression and its co-expression gene, it was found that
LOC105375434 and its co-expression gene.The present invention provides new biomarker for the early detection of colorectal cancer, has
Potential clinical value.
Summary of the invention
The purpose of the present invention is to provide a kind of long-chain non-coding RNA LOC105375434 relevant to colorectal cancer, sequences
Column have 90% or more sequence homology with SEQ ID NO.1.Preferably, LOC105375434 sequence and SEQ ID NO.1 have
There is 95% or more sequence homology；It is furthermore preferred that long-chain non-coding RNA sequence is SEQ ID NO.1.
The purpose of the present invention is to provide the reagents of detection LOC105375434 gene expression dose in preparation colorectal cancer
Application in diagnostic tool.
Further, reagent is using sequencing technologies, nucleic acid hybridization technique or nucleic acid amplification technologies detection LOC105375434
Expression.
Sequencing technologies be mainly second generation sequencing technologies (mainly include 454 pyrosequencing of Roche,
IlluminaSolexa sequencing and ABI SOLID sequencing) and third generation sequencing technologies (mainly include single molecular fluorescence sequencing and receive
Metre hole sequencing).
Further, nucleic acid amplification technologies are selected from polymerase chain reaction (PCR), reverse transcriptase polymerase chain reaction (RT-
PCR), the amplification (TMA) of transcriptive intermediate, ligase chain reaction (LCR), strand displacement amplification (SDA) and based on nucleic acid sequence
It expands (NASBA).Wherein, PCR needs directly expand RNA reverse transcription at DNA (RT-PCR), TMA and NASBA before amplification
RNA。
Further, using second generation sequencing technologies, third generation sequencing technologies, probe hybridization technique, biochip technology or
The expression of fluorescent quantitative PCR technique detection LOC105375434.
Further, reagent includes a pair of primer for being used for quantitative fluorescent PCR nucleic acid amplification, sequence be SEQ IDNO.2 and
SEQ ID NO.3。
Further, the sample of reagent detection is cancerous tissue or blood.
Further, colorectal cancer is colon cancer or the carcinoma of the rectum.
The purpose of the present invention is to provide the reagents for detecting gene expression dose relevant to LOC105375434 to prepare
Application in diagnosis of colorectal carcinoma tool, gene relevant to LOC105375434 are one or several in following gene:
DDX39A、TCF19、HMGB1、HIST1H3D、DSN1、SRPK1、TGDS、LBR、ADM5、CEP78、PRKCB、WAS、CPEB3、
KLF9、UST、SCIN、CD7、ACKR2、RCAN1、TP53INP2。
Relevant gene includes positive correlation gene or negative correlation gene.
Further, positive correlation gene be DDX39A, TCF19, HMGB1, HIST1H3D, DSN1, SRPK1, TGDS, LBR,
ADM5、CEP78。
Further, negative correlation gene be TP53INP2, RCAN1, ACKR2, CD7, SCIN, UST, KLF9, CPEB3, WAS,
PRKCB。
Further, reagent is using sequencing technologies, nucleic acid hybridization technique, nucleic acid amplification technologies or the detection of the method for immunoassays
Gene expression dose relevant to LOC105375434.
Term " homologous " be primarily referred to as it is homologous in sequence, that is, be used to illustrate two or more protein or DNA
Sequence ancestors having the same.Homologous sequence generally has similar function.The homology of protein and DNA are often through them
The similitude of sequence determines, similitude refer to be used to describe during sequence alignment it is between detection sequence and target sequence identical
The height of DNA base or amino acid residue sequence proportion.In general, when similarity degree is higher than 50%, often speculate inspection
Sequencing column and target sequence may be homologous sequence；When degree of similarity is lower than 20%, just it is difficult to determine if to have same
Source property.
It would be recognized by those skilled in the art that the invention is not limited to any specific variants to LOC105375434
Gene expression is quantified.In some embodiments, have same or similar with LOC105375434 sequence at least 85%
CDNA sequence, such as above-mentioned listed sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%
Or at least 99% the same or similar cDNA sequence.
In general, PCR uses the annealing of denaturation, primer pair and opposite strand and multiple circulations of primer extend, with index side
The copy number of formula increase target nucleic acid sequence；Reverse transcriptase (RT) is then used for the DNA (cDNA) complementary from mRNA preparation by RT-PCR,
Then cDNA is generated to multiple copies of DNA by PCR amplification；TMA is in substantially constant temperature, ionic strength and pH
Under the conditions of autocatalytically synthesize multiple copies of target nucleic acid sequence, wherein multiple RNA copy of target sequence is autocatalytically given birth to
At other copy, TMA is optionally included using blocking, part, terminate part and other modified parts, to improve TMA process
Sensitivity and accuracy；LCR uses the two groups of complementary DNA oligonucleotides hybridized with the adjacent area of target nucleic acid.DNA few nucleosides
Acid is covalently attached in thermal denaturation, hybridization and the multiple circulations of the repetition of connection by DNA ligase, to generate detectable double-strand
Connect oligonucleotide product；SDA uses multiple circulations of following steps: primer sequence pair and the opposite strand of target sequence move back
Fire carries out primer extend under there are dNTP α S to generate (hemiphosphorothioated) of half thiophosphorylation of double-strand
Primer extension product, the nicking that the endonuclease that semi-modified restriction enzyme enzyme recognition site carries out mediates, and from cutting
The polymerase-mediated primer extend that the mouth end 3' carries out is to replace existing chain and generate for next round primer annealing, nicking and displacement
Chain, so as to cause product geometry expand.
In the present invention " probe " refer to can be with the molecule in conjunction with the particular sequence of another molecule or subsequence or other parts.It removes
Non- to indicate otherwise, term " probe " is often referred to match and another polynucleotides (often referred to as " target multicore glycosides by complementary base
Acid ") combine polynucleotide probes.According to the preciseness of hybridization conditions, probe energy and with the probe lack sufficient sequence it is complementary
Property target polynucleotide combine.Probe can make direct or indirect label, and range includes primer.Crossing system, including, but not
It is limited to: solution phase, solid phase, mixed phase or in situ hybridization measuring method.
The probe has the base sequence with the specific base sequence complementary of target gene.Here, so-called " complementation ",
As long as hybridization, can not be complete complementary.These polynucleotides have usually relative to the specific base sequence
80% or more, preferably 90% or more, more preferable 95% or more, particularly preferred 100% homology.These probes can be DNA,
It is also possible to RNA, furthermore it is possible to pass through PNA (Polyamide nucleic in part of it or whole nucleotides
Acid, peptide nucleic acid), LNA (registered trademark, lockednucleic acid, Bridged Nucleic Acid, Cross-linked core
Acid), ENA (registered trademark, 2 '-O, 4 '-C-Ethylene-bridged nucleic acids), GNA (Glycerol
Nucleic acid, glycerol nucleic acid), the artificial replacement nucleic acid such as TNA (Threose nucleic acid, threose nucleic acid) obtains
Polynucleotides.
Term " hybridization " in the present invention is used to refer to the pairing of complementary nucleic acid.Hybridization and intensity for hybridization are (that is, between nucleic acid
Association intensity) influenced by factor such as below: the stringency of complementarity, related condition between nucleic acid is formed
Hybrid Tm and nucleic acid in G:C ratio.The individual molecule of pairing in its structure containing complementary nucleic acid is known as " self
Hybridization ".
Nucleic acid hybridization technique in the present invention include but is not limited in situ hybridization (ISH), microarray and Southern or
Northern trace.In situ hybridization (ISH) be it is a kind of use label complementary DNA or RNA chain as probe with position tissue one
Part or slice (original position) or if organize it is sufficiently small if for entirely organize (full organization embedding ISH) in specific DNA or
The hybridization of RNA sequence.DNA ISH can be used for determining the structure of chromosome.RNA ISH is for measuring with position tissue slice or entirely
MRNA and other transcripts (for example, ncRNA) in organization embedding.Usually sample cell and tissue are handled in situ solid
Targeting transcript, and increase the entrance of probe.Probe hybridizes with target sequence at high temperature, then washes off extra probe.Point
Not Shi Yong autoradiograph, fluorescence microscopy or immunohistochemistry, in tissue with radiation, fluorescence or antigenic mark base
The probe of label is positioned and is quantified.ISH can also be used two or more to pass through radioactivity or other nonradioactive labelings
The probe of substance markers, to detect two or more transcripts simultaneously.
Detailed description of the invention
Fig. 1 is the co-expression gene network of LOC105375434；Triangle be with LOC105375434 negative correlation gene,
Ellipse is and LOC105375434 positive correlation gene；
Fig. 2 is the qRT-PCR verification result figure of difference expression gene LOC105375434.
Specific embodiment
The present invention is described in further detail with reference to the accompanying drawings and examples.Following embodiment is merely to illustrate this
It invents rather than limits the scope of the invention.Test method without specific conditions in embodiment, usually according to conventional strip
Part, or according to the normal condition proposed by manufacturer.
The acquisition of 1 sample of embodiment is extracted and data analysis
It collects and carries out 4 rectal adenocarcinoma patient with operation cancers and cancer beside organism in this hospital, be put into and used 0.1%DEPC water logging
It steeps overnight and in the 1.5ml sterile EP tube sterilized, and is quickly put into -80 DEG C of liquid nitrogen container and saves.It is constructed after extracting sample rna
Then the library lncRNA and mRNA is surveyed mRNA with llumina hiseq x-ten second generation high throughput sequencing technologies
Sequence.By the processes such as removing connector, going low quality, depollute complete the processing of data, sequencing data is obtained.
MRNA, which is carried out, using software cuffquan, cuffdiff expresses quantitative and Differential expression analysis.Cuffquant is
It is specifically used to carry out expression quantity assessment and standardized tool in Cufflinks external member, cuffdiff is in Cufflinks external member
For calculating a tool of differential expression, cuffdiff utilizes the more each gene/transcript of quantitative result of cuffquant
Differential expression between two groupings.Significant difference lncRNA and mRNA screening conditions: P<0.05, | log2FC |>1.Significant
LOC105375434 is selected to carry out subsequent authentication experiment as target gene in difference lncRNA.
The co-expression gene of 2 LOC105375434 of embodiment is analyzed
As a kind of non-coding RNA, function is mainly reflected in the regulation to target gene lncRNA, mainly include to away from
Trans acting regulatory (trans-regulate) from protein coding gene farther out, meanwhile, the gene with identical expression pattern,
Functionally there is strong correlation.Therefore pass through the target base to lncRNA and mRNA coexpression, trans analysis and research lncRNA
Cause.
By the Pearson correlation coefficients (Pearson for calculating differential expression lncRNA and mrna expression amount
Correlation coefficient, PCC), analyze lncRNA and mRNA coexpression relationship, threshold value using 0.98, p <
0.001 screening with LOC105375434 coexpression mRNA (being specifically shown in Fig. 1), DDX39A, TCF19, HMGB1, HIST1H3D,
DSN1、SRPK1、TGDS、LBR、ADM5、CEP78、PRKCB、WAS、CPEB3、KLF9、UST、SCIN、CD7、ACKR2、RCAN1、
TP53INP2.Wherein, positive correlation gene be DDX39A, TCF19, HMGB1, HIST1H3D, DSN1, SRPK1, TGDS, LBR,
ADM5,CEP78；Negative correlation gene be TP53INP2, RCAN1, ACKR2, CD7, SCIN, UST, KLF9, CPEB3, WAS,
PRKCB。
The quantitative fluorescent PCR of 3 differential expression lncRNA of embodiment is verified
1, sample collection and extraction
Sample collection chooses this hospital and is diagnosed as the peripheral blood 28 of colon cancer or rectal cancer patient (wherein colon cancer is
13, the carcinoma of the rectum is 15), healthy population peripheral blood 24 for physical examination are compareed, QIAGEN blood rna extracts kit is utilized
Extract the RNA in serum, specific steps reference book.
2, reverse transcription:
1) the total serum IgE template of 10pg-1 μ g and 2 10 × buffers of μ l, 2 μ l dATP (10mM), 0.5 μ l polyA is more
Poly- enzyme, 0.5 μ l ribalgilase (RNase) inhibitor and deoxyribonuclease water (RNase free water) mixing, volume
It is finally 20 μ l, 37 DEG C of incubation 1h.
2) 1 μ l 0.5 μ g/ μ l Oligo (dT) specific RT primer, 70 DEG C of incubation 5min are added in reaction tube.
3) it is incubated at least 2min on ice immediately, interrupts the secondary structure of RNA and primer.
4) by above-mentioned 20 μ l reaction mixture and 45 × buffers of μ l, 1 μ l dNTP (10mM), 0.5 μ l M-MLV is reversed
Record enzyme, 0.5 μ l ribalgilase (RNase) inhibitor, 10 μ l polyA reaction mixtures and 4 μ l deoxyribonuclease water
(RNase free water) mixing, 42 DEG C of incubation 1h.
3、QPCR
(1) design of primers
QPCR amplimer is designed according to LOC105375434 sequence (XR_001744973.2) in Genbank, by Shanghai
The synthesis of Sheng Gong biotechnology Services Co., Ltd, internal reference select GAPDH.Specific primer sequence is as follows:
LOC105375434 gene:
Forward primer is 5 '-CTTGGCAGTGAGTGTAAC-3 ' (SEQ ID NO.2)
Reverse primer is 5 '-TGTTGGCATTCTTCTCTTC-3 ' (SEQ ID NO.3)
Amplification length 196bp.
(2) PCR reaction system is prepared according to table 1:
Wherein, SYBR Green polymerase chain reaction system is purchased from Invitrogen company.
1 PCR reaction system of table
| Reagent | Volume (μ l) |
| Upstream primer | 1 |
| Downstream primer | 1 |
| SYBR Green polymerase chain reaction system | 12.5 |
| Template | 2 |
| Deionized water | Filling-in is to 25 μ l |
(3) PCR reaction condition: 95 DEG C of 10min, (95 DEG C of 10s, 59 DEG C of 60s) × 35 circulations.Using SYBR Green as
Fluorescent marker carries out PCR reaction on Light Cycler fluorescence quantitative PCR instrument, true by melt curve analysis analysis and electrophoresis
Determine purpose band, Δ Δ CT method carries out relative quantification.
1.5 statistical method
Experiment is all to be repeated 3 times according to each sample to complete, and result data is all the side with mean+SD
Formula indicates, using SPSS13.0 statistical software come for statistical analysis, difference between the two is examined using t, it is believed that works as P
There is statistical significance when < 0.05.
1.6 result
Real-time quantitative PCR amplification curve inflection point understands that amplification curve entirety collimation is good, shows the amplification effect of each reaction tube
Rate is close, and the limit is flat and present without raising up, and exponent phase slope is larger, illustrates that amplification efficiency is higher；Sample amplified production is molten
Solution curve be all it is unimodal, illustrate that amplified production only has one, be specific amplification；According to the relative quantification formula of qRT-PCR: 2-
Δ Ct × 100%.As a result as shown in Fig. 2, compared with Healthy People group, there is aobvious LOC105375434 gene expression amount in illness group
It writes and increases, be 2.32 times of Healthy People group, difference has statistical significance (P < 0.05).With 24 healthy population cell means
To detect baseline, in 28 colorectal cancer patients, 21 LOC105375434 gene expression amounts have a significant raising, and 5
LOC105375434 gene expression difference is not statistically significant, and 2 expression are lowered, and compares colon cancer and rectal cancer group
LOC105375434 gene is not statistically significant in two groups of differential expression.Show LOC105375434 gene pairs colorectal cancer
Diagnosis has certain guidance meaning, is expected to become the candidate markers of colorectal cancer molecular diagnosis in clinic or human health screening.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Sequence table
<110>No.3 Central Hospital of Tianjin City
<120>a kind of colorectal cancer biomarker
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6250
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
gcttactttc agatcgcatg aacgcattcc tggacaccag ccacagttgc taaaactaaa 60
tgggatcctg cagacccatt gacggactgt catagccaac tcaatcacag tcgagaagca 120
tttgaatact tacagcctat ggcgctagga tcctggtagc gaagaaacta aactctaatt 180
tgaaatgttg tacagctagc ttagagtggc tgctgaactt aagggtgatt aagagctgct 240
tgcacctggg tggagctgaa actgcataag gtgaataata cctttgtgca acagaagaaa 300
aaaaaaaaag taacagcata catacaaacc caaaggggtc tgtacagtaa aaggaaaaga 360
taatgaggta acaagtaatg cagaatgtct ctctgatcac aagtcaaaat gtggaagtgc 420
gtttcacaca tcaaaggtgg gacttcgttc ctggcactga tctctatttg agctccgctt 480
ttgtagactc tacaacaatt aggttagctc atgaatgcta atttatccca cagggcacag 540
tagatataca gtaatggcta gaaaatggtt tgaaacttta acctgggatg ccagaggttt 600
gcctcccaga cccccacttg tctcctctgc ttggccccag cttggctgca gtgcaggcaa 660
ccagagcagg actcacccta tctcccctct ccctggaaga gaaacagaaa gagcgtgatg 720
atgatggatg gaggaaggga gaagtgaatc aaggtgcaag actgagagct gatgaagagt 780
catgaaatat cttggagaaa attttctcaa ataccctttt ttcctggagt tactcaagca 840
caagatacat ttctggagtc agccaagaaa caggcccatg gaattttaag agtcaagaaa 900
acaaaagaaa tccaggctta gccagcctat agatttgtgt atgggcatga tacaaagcat 960
taatgataca tttgttcttt atgccccaaa attagaagac tgatacacca tcaaggaaaa 1020
cccccagaaa agggaaaagc cttacaatag caaataaaaa gagccctaca aaactagcct 1080
ttaccaagtt ctagggactg tctaaggata tcacatatac taccttgttt aattctcaca 1140
ggcgcctaca agatgcatcc tttcattatc ctcaatttgt aggagaaaga actcagagag 1200
gctgaggaaa cttgctcaag gttatatcac tagttagcgg tggagctggg gtgtgaactc 1260
agaccactgt tcctaaccct tgacactaca ctgtcttgtg agatggacaa ttcataaaag 1320
ataacaacat gagttttttt cccttaaaac taaaaattgc ttccttgaaa ataaagatgc 1380
ttagagccga ccctaagaat cacagcccat cctaagaaag tatgttcagt gcaattgagt 1440
gtggcaaatt atggggatta acttgaattc tctttatgta ttacaaagta agtcattagt 1500
agactttgga actctgttgt tagtaacaaa tgtcttacac cccagctcat tgcaacaccc 1560
cagtgtgctg tgataccacc atggctggga accattggcc tggaaaatag acctaggcag 1620
aaagatattt atgtaactga gttgaagaag gtagctggaa ggtgcatgaa gctagacatt 1680
ggcagtgtgt gtcaggtgct acagcttagg gccttcctgg aaaatgggca ggaaaaatag 1740
acggtgacaa aacaaacaca tcagtattat gggtaagcct gcagagataa gttctggggc 1800
attctgctgc ctgccaagac tacataagtc ccaggagcca cagcatttgt tgcataagat 1860
taaatcactc caagctgaga atttccccct ttaaaggaat aaatggcaag ccatggggga 1920
aagaatgagc caacgcttct aggacatgtg tgcctccact taggcatttt ggtcccttga 1980
ccctccaaga cattgatgtg actttggcca agtcactggt tgttaccaag aggggatgaa 2040
atacatgttt ccctaaatcc cttccaactc aaaaaatatg ggatactttg aataaaatga 2100
gattggtaca aaattctgat tacctttgag aatgtctagc tctgattgct agattttcac 2160
tgcatatttt cctctagcct tcaattatct cccaataatt tacccccaaa tctttattac 2220
ttcaaatgaa tagacttttc atagagccct actgcatctc tagtccacag acactaagac 2280
atacattagc attattaaat tgtaagccaa agacatatct atatatctaa atactgtgtt 2340
tgcatgcttt ccctgatcat tatgtacttt ttccccattc cattaccact taaaatgcat 2400
tttgtgatat ttcattaaag aggcataatt acattagaga agtttgtttt cagacatcaa 2460
catgtgcctt tgggttacat ttcacattat gaagatggac ttaaaagaga taacaccatt 2520
tagtgtgcta attatcacaa gattctcaaa gtgcgccaga ctctaggtgc ttttgctgtt 2580
taagaaatgt gactgtaaaa acttccactc atgaagctta gcatgcattg actacctact 2640
atggattggg cttgatattg aggatagaga agaacaaaac aagtctagca gagcaggaaa 2700
gtgtgtgtgt aaatacgttg tagccaccac cctctggagt ggctctccat ttcaccaaga 2760
atcccttagg ccctccccag cagcactctt tccccttcta tgcccaggag cctgcaccac 2820
aattgtatta tgtgatgtag ccctgaatgg ataatggccc ctgcacaacc aggcaacatt 2880
gtctctccca ggaatttgaa cctttaacta agagttttaa tttagcctgg gcaagcctgg 2940
tgaatgacag actcaaaact gaagattatg gagcagccac ttctgcttgt tatgttggct 3000
gagaagtaga aatatagaaa taatcagtgt gcagagtaga gtgcagcaga gagagagaaa 3060
caaggatgga ggagggagaa agaataatta gatgactgaa tgaatcctgg agagccttgc 3120
ttcccaccag ttgttggttc cagaccctcc agccgcattc caacacccca gtgcttgagg 3180
ccccctacat ttcctttttt gtggttttag ccttgatttt ttttttcttt ggaaccaaga 3240
gttccaacta ataaatgagt gtaataactt gttattggca ttataatgga agtgggtaca 3300
gaacaaattt taacctatct tatttataca aatagagtac agatgtcaat tgtacttaat 3360
gttaaatagg ccaatgacaa ctcatttttg ttcttaaatc ctttccacta taaacattta 3420
tgcacagcaa catttgcaag acactgagcc ttggcagtga gtgtaacaag atgcatagca 3480
atggtgggca accttatttt gatcaagaga aaattaggaa aaagcaaaaa ttacttacag 3540
gctatatttc tctctcattc aaaatggctt tattgttgat cttatgggga aaattgtatt 3600
tttgcaactc aggtgattta tttattgaag agaagaatgc caacaagaaa actttttcgg 3660
cctctgaaag attataacat gttccggttt aaggatttgt aactccagac agctctaatt 3720
gtccatctct tatgtttgga ctgcacctta attttcacca catgagttca tctgcattag 3780
ccccaagtat ccttccatcc ccctcatcaa caaaatctgg cccatgaggt attattatcc 3840
tcatttagag gatatggaga aattaaggct ctgtttcaaa gcaagtctgt aaattcttta 3900
acattcttcc catcaagaag agagatctat ctcctgccct ggaacatggg cagcgctttt 3960
gactgtctcc gtgcatataa tatggtggaa gtgacactgc ttgacttgtg aagctggatc 4020
acaatgggtt attgacttcc accagcctgt ctccggggac aggtgacttc atgtaagaag 4080
tccagctacc ctgacagaga gtccacattg gagggagcac actgtaatag acagaggtgc 4140
ctgaggagcc ccggctgttc cagccgccag ctatttaggt cttcccaagt caggcaccag 4200
agagtatgaa tggaaaggcc ttcaagagaa ctctagcccc agccattgtc tgattgtcac 4260
tgcatgagga ccaaaaacta cctagctgag ccccatcaac ccctaaagaa gtgaaagata 4320
gtaatgacaa atgcttgctg ttgttttata gcaccaagct ctgagtggtt tgttgtgctg 4380
caggctccaa gagaagtaac tttctgagag cactcaggaa tttcttagtg gaactggggc 4440
tagaatcaat tcactgcatt taatgcagta ttaaccagac aactgtgttg ggccctgggg 4500
accagagaag aattaacaca cagcccaagc cttcccctgg tctgagcttc ctcttcccac 4560
cttcatattc atggcagctt cttcttgctg ggagtgggat agaggagccc tagggctgct 4620
ggcttctgga aggaactggc tccagggcac cctggctatt cccttgctcc atgctgtgtg 4680
caggtggctc tggcaccaag aggtggcacc aaacctgctg ccagccttgg ctttctcacc 4740
agtcctgctc tgatgagttg acaggctgtg tttggaattg agcatggcgg tattacaaag 4800
gcaagtgggt accacacaac ctgcccgcag tgttgctttg ttctgatgaa ttacactgag 4860
tccctggatt cacatttggc tggattgtca ggaaaaatat gtgttctggg tgccacctga 4920
tcttttcatc tagcttctgt cctcaggtaa acattccctg ttaaaattct aaatgttcat 4980
ctgcttcctc taaagagatt ggtaaaaagg cataaaacac ctaagaatca gtgttacttg 5040
taatgagccc agggctgccg cagggagcac catatacata gaataccagg tgagtgagtg 5100
gggccctcag ggctgaagta ttatgctcta ggccagaaaa aggatatttt ctttttattc 5160
ctgggataca gataatgtat tttcacataa cagccacatg tttcatgaat taagccaaca 5220
aatatttacc aagtatcctt taaatccttt agtatttaaa gtatcatttt ttgcaaaaaa 5280
aaaaaaaata tgagggccaa cttatttttg cctgtcatga aatcaaaggc caattaaata 5340
atcatttcca aatttatatt tctgttttat aggttttctt tattcaaggc attcttgtac 5400
agtaaagggc aggaaaagga gagggagagg gaaagggaga agaggaagaa ggaggaaggt 5460
gtgtgtgttg ggagtagggg gaagctttgc aaatggtaaa cctgggttat tatttgactt 5520
ttggttaaaa aaaaaagttg catcaaatta agcagtaagc aatcatgaag caggcagtga 5580
catgcataga gcagattttc ctaaatcatc ttccccagaa caccaattcg ctaagatgtt 5640
aataagcatt ttccaaataa agattttcat ttttcagata aattcaggac cggctgcatc 5700
tccactcctg aattagagga gacagcactg attgcagtga cagaagcggt gccagctaac 5760
tccccaccat caaaagtatc ttctgctgta gcctggcaca agtttcaagc atccactggg 5820
ggtcttggga tgtgtcgccc tgcagataag ggcaactgct gtgcagcatg aacagtatgg 5880
agacaatact tatcttcatg gagtttatat tagagtaaga caagaggtag gagactgcct 5940
attttattgt tctcttgaaa agactgggta ttttactttt atgaaaggct ttatagcctg 6000
caggggcatt ctaatatgga ttttgggggt gaagagacaa ataggtgtgg aaagtaagtt 6060
caggggttca gagacccata ggttttttaa aagagaagtc aggggaaggt ctcttaaggt 6120
agtagtggag tccaaattat tctatgtccc ttgtagctcc taccctttgt atgcagtagt 6180
ttttttttta aatcgaagac gggggaaggt ctcttaaggt aatagtagag accaaattat 6240
tctatctccc 6250
<210> 2
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
cttggcagtg agtgtaac 18
<210> 3
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
tgttggcatt cttctcttc 19
Claims (10)
1. a kind of long-chain non-coding RNA LOC105375434 relevant to colorectal cancer, sequence have with SEQ ID NO.1
90% or more sequence homology.
2. detecting application of the reagent of LOC105375434 gene expression dose in preparation diagnosis of colorectal carcinoma tool.
3. application according to claim 2, which is characterized in that reagent uses sequencing technologies, nucleic acid hybridization technique or nucleic acid
Amplification technique detects the expression of LOC105375434 in sample.
4. application according to claim 2, which is characterized in that skill is sequenced using second generation sequencing technologies, the third generation in reagent
Art, probe hybridization technique, biochip technology or fluorescent quantitative PCR technique detect the expression of LOC105375434, preferably
, the primer sequence of quantitative fluorescent PCR nucleic acid amplification is SEQ ID NO.2 and SEQ ID NO.3.
5. application according to claim 2, which is characterized in that the nucleic acid amplification technologies are selected from one of the following or several
Kind: polymerase chain reaction, reverse transcriptase polymerase chain reaction, the amplification of transcriptive intermediate, ligase chain reaction, strand displacement expand
Increasing and the amplification based on nucleic acid sequence.
6. application according to claim 3, which is characterized in that it is cancerous tissue or blood that reagent, which detects sample,.
7. application according to claim 2, which is characterized in that colorectal cancer is colon cancer or the carcinoma of the rectum.
8. detecting reagent the answering in preparation diagnosis of colorectal carcinoma tool of gene expression dose relevant to LOC105375434
With, which is characterized in that gene relevant to LOC105375434 is one or several in following gene: DDX39A,
TCF19、HMGB1、HIST1H3D、DSN1、SRPK1、TGDS、LBR、ADM5、CEP78、PRKCB、WAS、CPEB3、KLF9、UST、
SCIN、CD7、ACKR2、RCAN1、TP53INP2。
9. application according to claim 8, which is characterized in that relevant gene includes positive correlation gene or negatively correlated base
Cause, positive correlation gene are DDX39A, TCF19, HMGB1, HIST1H3D, DSN1, SRPK1, TGDS, LBR, ADM5, CEP78, are born
Related gene is TP53INP2, RCAN1, ACKR2, CD7, SCIN, UST, KLF9, CPEB3, WAS, PRKCB.
10. application according to claim 8, which is characterized in that reagent uses sequencing technologies, nucleic acid hybridization technique, nucleic acid
Amplification technique or the method for immunoassays detect gene expression dose relevant to LOC105375434.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910173715.XA CN109735623B (en) | 2019-03-07 | 2019-03-07 | Colorectal cancer biomarker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910173715.XA CN109735623B (en) | 2019-03-07 | 2019-03-07 | Colorectal cancer biomarker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109735623A true CN109735623A (en) | 2019-05-10 |
| CN109735623B CN109735623B (en) | 2022-01-18 |
Family
ID=66369857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910173715.XA Expired - Fee Related CN109735623B (en) | 2019-03-07 | 2019-03-07 | Colorectal cancer biomarker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109735623B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110229899A (en) * | 2019-06-19 | 2019-09-13 | 广州医科大学附属第三医院 | For colorectal cancer early diagnosis or the plasma markers object combination of prognosis prediction |
| CN112921083A (en) * | 2021-03-31 | 2021-06-08 | 青岛泱深生物医药有限公司 | Genetic markers in the assessment of intestinal polyps and colorectal cancer |
| CN113151465A (en) * | 2021-03-31 | 2021-07-23 | 青岛泱深生物医药有限公司 | Products and related applications for identifying polyps and cancers based on genetic markers |
| CN113151439A (en) * | 2021-03-31 | 2021-07-23 | 青岛泱深生物医药有限公司 | Gene marker for distinguishing intestinal polyp and colorectal cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753974A (en) * | 2018-06-27 | 2018-11-06 | 深圳华大生命科学研究院 | A kind of colorectal cancer tumor markers and its detection method and device |
| CN108841957A (en) * | 2018-07-03 | 2018-11-20 | 上海柏运医疗器材有限公司 | The diagnosing cancer of liver marker and diagnostic kit being made of blood plasma circular rna |
-
2019
- 2019-03-07 CN CN201910173715.XA patent/CN109735623B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753974A (en) * | 2018-06-27 | 2018-11-06 | 深圳华大生命科学研究院 | A kind of colorectal cancer tumor markers and its detection method and device |
| CN108841957A (en) * | 2018-07-03 | 2018-11-20 | 上海柏运医疗器材有限公司 | The diagnosing cancer of liver marker and diagnostic kit being made of blood plasma circular rna |
Non-Patent Citations (2)
| Title |
|---|
| NCBI: "REDICTED: Homo sapiens uncharacterized LOC105375434 (LOC105375434), transcriptariant X2,ncRNA", 《GENBANK DATABASE》 * |
| 常顺伍等: "miR-503在结直肠癌组织细胞中的表达及其对增殖和诱导细胞凋亡的影响", 《广东医学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110229899A (en) * | 2019-06-19 | 2019-09-13 | 广州医科大学附属第三医院 | For colorectal cancer early diagnosis or the plasma markers object combination of prognosis prediction |
| CN110229899B (en) * | 2019-06-19 | 2024-04-09 | 广州医科大学附属第三医院 | Plasma marker combinations for early diagnosis or prognosis prediction of colorectal cancer |
| CN112921083A (en) * | 2021-03-31 | 2021-06-08 | 青岛泱深生物医药有限公司 | Genetic markers in the assessment of intestinal polyps and colorectal cancer |
| CN113151465A (en) * | 2021-03-31 | 2021-07-23 | 青岛泱深生物医药有限公司 | Products and related applications for identifying polyps and cancers based on genetic markers |
| CN113151439A (en) * | 2021-03-31 | 2021-07-23 | 青岛泱深生物医药有限公司 | Gene marker for distinguishing intestinal polyp and colorectal cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109735623B (en) | 2022-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111961725B (en) | Kit or device for detecting pancreatic cancer and detection method | |
| CN109735623A (en) | A kind of colorectal cancer biomarker | |
| CN117987555A (en) | Kit, device and method for detecting ovarian tumor | |
| CN108949992B (en) | Biomarker related to esophageal squamous carcinoma and grading thereof | |
| CN103014155A (en) | New markers for cancers | |
| SG192108A1 (en) | Colon cancer gene expression signatures and methods of use | |
| CN108676872B (en) | One kind biomarker relevant to asthma and its application | |
| CN106337089B (en) | A kind of lncRNA for cerebral arterial thrombosis diagnosis | |
| AU2017228649A1 (en) | Methods for predicting drug responsiveness in cancer patients | |
| CN106676191B (en) | A kind of molecular marker for adenocarcinoma of colon | |
| CN109735622A (en) | LncRNA relevant to colorectal cancer and its application | |
| EP3978631A1 (en) | Squamous cell cancer diagnostic or prognosis prediction marker and use thereof | |
| CN108949969B (en) | Application of long-chain non-coding RNA in colorectal cancer | |
| EP3390661B1 (en) | Use of antisense long non-coding rnas for the diagnosis of prostate cancer | |
| CN107164519A (en) | A kind of primer and probe that ESR1 gene mutations are detected based on fluorescent PCR | |
| WO2020084035A1 (en) | Use of long non-coding rna for the diagnosis of prostate cancer | |
| EP2942399B1 (en) | Method for the diagnosis of breast cancer | |
| CN102827935B (en) | Reagent kid for quantitatively testing mRNA (messenger ribonucleic acid) level of FIP1L1-PDGFRA (feline infectious peritonitis 1 like 1-platelet-derived growth factor receptor alpha) fusion genes | |
| CN112646885B (en) | Kidney cell carcinoma miRNA molecular marker and application thereof | |
| CN109504773A (en) | A kind of biomarker relevant to oral squamous cell carcinomas differentiation grade | |
| WO2015115544A1 (en) | Evaluation method for risk of metastasis or recurrence of colon cancer | |
| EP2622097B1 (en) | Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse | |
| CN110117656A (en) | A kind of biomarker relevant to sdenocarcinoma of stomach occurrence and development | |
| US20120157342A1 (en) | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor | |
| KR102152893B1 (en) | Use for detection of hepatocellular carcinoma specific MLH1 circulating tumor DNA mutation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220118 |